Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeltje Steeghs

Showing results (11-20 of 206) with videos related to

Pageof 21
Sort By:
Clinical Pharmacokinetics|February 11, 2017
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingRemy B Verheijen, Jos H Beijnen, Jan H M Schellens, et al.
Cancers|July 14, 2023
Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical ChallengesJason van Leuven, Simon Evans, Ganessan Kichenadasse, et al.
European Journal of Clinical Pharmacology|June 9, 2019
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicineStefanie L Groenland, Ron H J Mathijssen, Jos H Beijnen, et al.
Clinical Pharmacokinetics|July 21, 2016
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour PatientsSheima Farag, Remy B Verheijen, J Martijn Kerst, et al.
Therapeutic Drug Monitoring|February 7, 2024
Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and MetabolitesMarinda Meertens, Niels de Vries, Hilde Rosing, et al.
Journal of Clinical Pharmacology|March 27, 2015
Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumorsSheima Farag, Arjan J Verschoor, Jacob W Bosma, et al.
Cancer Chemotherapy and Pharmacology|October 31, 2023
Are novel oral oncolytics underdosed in obese patients?Lishi Lin, Ellen K O van der Meer, Neeltje Steeghs, et al.
Frontiers in Pharmacology|September 16, 2021
A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer DrugsLaura Molenaar-Kuijsten, Dorieke E M Van Balen, Jos H Beijnen, et al.
Critical Reviews in Oncology/Hematology|June 20, 2025
Targeting the DNA damage response to enhance radiotherapy in soft tissue sarcomasBauke H G van Riet, Sanne Venneker, Judith V M G Bovée, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2024
A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinibLishi Lin, Vincent van der Noort, Neeltje Steeghs, et al.
Pageof 21

Showing results (11-20 of 206) with videos related to

Sort By:
Pageof 21
Clinical Pharmacokinetics|February 11, 2017
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingRemy B Verheijen, Jos H Beijnen, Jan H M Schellens, et al.
Cancers|July 14, 2023
Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical ChallengesJason van Leuven, Simon Evans, Ganessan Kichenadasse, et al.
European Journal of Clinical Pharmacology|June 9, 2019
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicineStefanie L Groenland, Ron H J Mathijssen, Jos H Beijnen, et al.
Clinical Pharmacokinetics|July 21, 2016
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour PatientsSheima Farag, Remy B Verheijen, J Martijn Kerst, et al.
Therapeutic Drug Monitoring|February 7, 2024
Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and MetabolitesMarinda Meertens, Niels de Vries, Hilde Rosing, et al.
Journal of Clinical Pharmacology|March 27, 2015
Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumorsSheima Farag, Arjan J Verschoor, Jacob W Bosma, et al.
Cancer Chemotherapy and Pharmacology|October 31, 2023
Are novel oral oncolytics underdosed in obese patients?Lishi Lin, Ellen K O van der Meer, Neeltje Steeghs, et al.
Frontiers in Pharmacology|September 16, 2021
A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer DrugsLaura Molenaar-Kuijsten, Dorieke E M Van Balen, Jos H Beijnen, et al.
Critical Reviews in Oncology/Hematology|June 20, 2025
Targeting the DNA damage response to enhance radiotherapy in soft tissue sarcomasBauke H G van Riet, Sanne Venneker, Judith V M G Bovée, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2024
A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinibLishi Lin, Vincent van der Noort, Neeltje Steeghs, et al.
Pageof 21